| Species |
Human |
| Protein Construction |
AXL (Ala26-Pro449)
Accession # P30530-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized AXL[Biotin], His & Avi, Human at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind AntiAXL Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
48.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers. |
| Synonyms |
Axl; UFO; AXL oncogene; AXL; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
